Stocks and Investing
Stocks and Investing
Wed, May 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 30, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gavin Clark-Gartner Maintained (CCCC) at Buy with Decreased Target to $10 on, May 30th, 2023
Gavin Clark-Gartner of Evercore ISI Group, Maintained "C4 Therapeutics, Inc." (CCCC) at Buy with Decreased Target from $20 to $10 on, May 30th, 2023.
Gavin has made no other calls on CCCC in the last 4 months.
There are 4 other peers that have a rating on CCCC. Out of the 4 peers that are also analyzing CCCC, 1 agrees with Gavin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $5 on, Tuesday, March 28th, 2023
These are the ratings of the 3 analyists that currently disagree with Gavin
- Terence Flynn of "Morgan Stanley" Maintained at Sell with Decreased Target to $3 on, Friday, May 12th, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $25 on, Monday, May 8th, 2023
- Eric Joseph of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $5 on, Friday, February 24th, 2023
Contributing Sources